Celltrion, Inc. Stock Korea S.E.
Equities
068270
KR7068270008
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- KRW | - |
|
Jul. 01 | S.Korean shares rise on robust data; battery, biopharma stocks jump | RE |
Jun. 17 | Celltrion Reveals Positive Phase III Results of Rheumatoid Arthritis Drug | MT |
Sales 2024 * | 3,447B 2.51B | Sales 2025 * | 4,254B 3.09B | Capitalization | 38,854B 28.25B |
---|---|---|---|---|---|
Net income 2024 * | 536B 390M | Net income 2025 * | 1,234B 897M | EV / Sales 2024 * | 11.5 x |
Net Debt 2024 * | 891B 648M | Net Debt 2025 * | 82.29B 59.83M | EV / Sales 2025 * | 9.15 x |
P/E ratio 2024 * |
75.1
x | P/E ratio 2025 * |
32.7
x | Employees | - |
Yield 2024 * |
0.25% | Yield 2025 * |
0.26% | Free-Float | 66.89% |
Managers | Title | Age | Since |
---|---|---|---|
Wu-Sung Ki
CEO | Chief Executive Officer | 62 | 07-04-23 |
Ho-Seop Lee
DFI | Director of Finance/CFO | 49 | - |
Jung-Jin Seo
CHM | Chairman | 66 | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Soon-Woo Lee
BRD | Director/Board Member | 73 | - |
Jung-Jin Seo
CHM | Chairman | 66 | - |
Jong-Seok Lee
BRD | Director/Board Member | 72 | 14-12-07 |
1st Jan change | Capi. | |
---|---|---|
+22.10% | 46.55B | |
+46.45% | 41.84B | |
-3.12% | 40.84B | |
+36.10% | 32.95B | |
+18.71% | 27.78B | |
+46.15% | 14.26B | |
+44.52% | 13.69B | |
+0.19% | 12.18B | |
-8.55% | 11.14B |
- Stock Market
- Equities
- A068270 Stock
- 068270 Stock